公开(公告)号：US20220112258A1

公开(公告)日：2022-04-14

申请号：US17278157

申请日：2020-07-27

Applicant: I-Mab Biopharma US Limited

Inventor： Feifei Cui ,  Lei Fang ,  Yuanyuan Yang ,  Zhengyi Wang ,  Bingshi Guo

IPC: C07K14/54 ,  C07K16/28 ,  A61P35/00

Abstract: Provided are polypeptides having an antigen-binding unit targeting a tumor antigen and an IL-7 protein or fragment thereof, fused to a Fc fragment. The disclosed polypeptides can be used for treating cancer.

公开(公告)号：US11261259B2

公开(公告)日：2022-03-01

申请号：US17286437

申请日：2020-08-12

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US20200347146A1

公开(公告)日：2020-11-05

申请号：US16963091

申请日：2019-07-25

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang ,  Qiumei Yang

IPC: C07K16/28

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.

公开(公告)号：US11208486B2

公开(公告)日：2021-12-28

申请号：US17277909

申请日：2020-04-26

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yuanyuan Yang ,  Zhengyi Wang ,  Bingshi Guo ,  Feifei Cui

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US20200377611A1

公开(公告)日：2020-12-03

申请号：US16989670

申请日：2020-08-10

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/68

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

公开(公告)号：US20200071403A1

公开(公告)日：2020-03-05

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

公开(公告)号：US12091467B2

公开(公告)日：2024-09-17

申请号：US16989702

申请日：2020-08-10

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/68

CPC classification number: C07K16/2896 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/30 ,  G01N33/6893 ,  A61K39/395 ,  C07K2317/56 ,  C07K2317/569 ,  G01N2333/70596

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

公开(公告)号：US20220119531A1

公开(公告)日：2022-04-21

申请号：US17563502

申请日：2021-12-28

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yongqiang Wang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US11034771B2

公开(公告)日：2021-06-15

申请号：US16963091

申请日：2019-07-25

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang ,  Qiumei Yang

IPC: C07K16/28

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

公开(公告)号：US20200332005A1

公开(公告)日：2020-10-22

申请号：US16785953

申请日：2020-02-10

Applicant: I-MAB Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/17 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.